Skip to main content
Home > BC Innovations > Strategy

Chronological Index of : Strategy

 Current Issue
  • Merck Encycles through Canada

    The first disclosed grant under Merck's 2013 initiative to fund Canadian innovation will support lead optimization of Encycle Therapeutics' macrocycle program for IBD.

    Published on 12/4/2014
  • Mixing it up at Karolinska

    Karolinska's new deputy vice chancellor, Alexander von Gabain, has plans to break down silos and breed new mindsets to maximize the institute's translational potential.

    Published on 11/20/2014
  • ACTing for NIH

    A new campaign to petition Congress to increase NIH funding has the backing of several academic heavyweights but stops short of defining how the money would be spent.

    Published on 11/6/2014
  • Bayer's Bay Area formula

    Bayer is emphasizing alliances rather than money to tap into Bay Area innovation.

    Published on 10/30/2014
  • The ALS bucket brigade

    The ALS Association is allocating the first funds from its ice bucket challenge to create four new research alliances that focus on genetics and biomarkers for the disease.

    Published on 10/30/2014
  • New CAR shopping

    Kite Pharma's Arie Belldegrun says that target selection is the most important and difficult aspect of early stage CAR T cell research.

    Published on 10/16/2014
  • Figure 1: New kinase inhibitors approved in U.S. by year

    Translational Notes: A conversation with Jeffrey Settleman Figure 1. New kinase inhibitors approved in U.S. by year. Counts for 2014 exclude Chugai Pharmaceutical Co. Ltd.'s Alecensa alectinib, a small molecule …

    Published on 10/2/2014
  • Table 1: Piloting progress in MS

    Translational Notes: Progressive thinking in MS Table 1. Piloting progress in MS. In the first stage of a 5-year initiative, the International Progressive MS Alliance has awarded approximately €75,000 ($95,640) to …

    Published on 10/2/2014
  • A conversation with Jeffrey Settleman

    SciBX spoke with Genentech's Jeffrey Settleman about resistance mechanisms against kinase inhibitors used to treat cancer and what should be done to tackle the problem.

    Published on 10/2/2014
  • Progressive thinking in MS

    The International Progressive MS Alliance is pushing for advances in progressive MS-an understudied form of the disease-by funding 22 projects in the pilot phase of its 5-year, €22 million ($28 million) initiative.

    Published on 10/2/2014
  • Canadian accelerant

    Two Canadian venture firms and a government-funded program have launched Canada's first national health science accelerator, Accel-Rx, to reignite local VC interest in funding early stage biotechs.

    Published on 9/25/2014
  • The FDA's push for better biomarkers

    The FDA is calling on stakeholders to help define a path for validating and approving biomarkers to enable their use in drug development.

    Published on 9/18/2014
  • Figure 1: Investing in the brain

    Translational Notes: Buckets of money for the brain Figure 1. Investing in the brain. (I) Number of public-private partnerships (PPPs) announced for neurology or cancer indications. Data include double counting as …

    Published on 9/11/2014
  • Figure 2: Neurology indications for PPPs formed since 2011

    Translational Notes: Buckets of money for the brain Figure 2. Neurology indications for PPPs formed since 2011. Data include double counting as some PPPs include multiple indications. Percentages are out of the total…

    Published on 9/11/2014
  • A conversation with Miguel Barbosa

    SciBX talked with Janssen's VP and head of immunology research and scientific partnership strategy about rethinking how to attack inflammatory bowel disease.

    Published on 9/11/2014
  • Buckets of money for the brain

    A few years ago, many companies threw in the towel on neurological diseases because poor understanding of their biology made R&D too risky. The field is finally receiving increased private and public funding, but some …

    Published on 9/11/2014
  • Table 1: Druggable projects

    Translational Notes: Funding forgotten proteins Table 1. Druggable projects. The NIH has allocated $5.8 million to fund 7 research projects that explore the biology of GPCRs, ion channels, kinases and nuclear …

    Published on 9/4/2014
  • Table 1: Allied Minds startups based in the life sciences

    Translational Notes: Meeting of the minds Table 1. Allied Minds startups based in the life sciences. Source: Allied Minds Startup Technology concept Products Origin of technology Biotectix LLC Next-generation …

    Published on 9/4/2014
  • Funding forgotten proteins

    A new NIH program is looking to fund understudied members of druggable protein classes by supporting exploratory projects at risk of being passed over because of a lack of preliminary data.

    Published on 9/4/2014
  • Meeting of the minds

    Allied Minds has partnered with Bristol-Myers Squibb to form Allied-Bristol Life Sciences LLC and can now add therapeutics to its portfolio of academia-based startups.

    Published on 9/4/2014
  • Table 1: Comparison of current awards to support nontraditional funding methods

    Translational Notes: Getting researchers off the grant treadmill Table 1. Comparison of current awards to support nontraditional funding methods. Source: NIH NIH Director's Awards National Cancer Institute …

    Published on 8/28/2014
  • Getting researchers off the grant treadmill

    The National Cancer Institute has created a generous seven-year award designed to ease the grant-writing burden for 'outstanding investigators'. Now the institute needs to ensure that the program is not just easier …

    Published on 8/28/2014
  • Industrial strength for Sanford-Burnham

    GSK executive Perry Nisen has joined Sanford-Burnham as CEO and plans to apply his industry know-how to accelerate drug development at the institute.

    Published on 8/28/2014
  • AstraZeneca taps the Cambridge wellspring

    AstraZeneca has unveiled plans for its R&D center and global headquarters in Cambridge, U.K. -- the next major step in the pharma's strategy to improve pipeline productivity to help it recover growth and regain ground …

    Published on 8/21/2014
  • Dementia public-private partnerships

    Translational Notes: AD mission in the U.K. Table 1. Dementia public-private partnerships. Selected public-private partnerships focused on dementia research initiated over the past five years. Date Title Companies…

    Published on 7/24/2014

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993